---
title: "Use of the Atkins Diet for Children With Intractable Epilepsy: A Comparison of Daily Carbohydrate Limits"
nct_id: NCT00181090
overall_status: COMPLETED
phase: PHASE1
sponsor: Johns Hopkins University
study_type: INTERVENTIONAL
primary_condition: Epilepsy
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00181090.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00181090"
ct_last_update_post_date: 2009-03-27
last_seen_at: "2026-05-12T06:53:25.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Use of the Atkins Diet for Children With Intractable Epilepsy: A Comparison of Daily Carbohydrate Limits

**NCT ID:** [NCT00181090](https://clinicaltrials.gov/study/NCT00181090)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Johns Hopkins University
- **Conditions:** Epilepsy
- **Start Date:** 2005-02
- **Completion Date:** 2006-09
- **CT.gov Last Update:** 2009-03-27

## Brief Summary

This study is designed to further investigate the use of a modified Atkins diet for children with intractable, daily seizures. It is a follow-up to a study recently completed by our institution. In this 6-month study, children will be randomized to either 10 or 20 grams of carbohydrate per day, then crossed over to the opposite amount at 3 months.

## Eligibility

- **Minimum age:** 3 Years
- **Maximum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Ages 3-18
* Daily seizures or 7 per week
* Failed at least 2 anticonvulsants

Exclusion Criteria:

* Prior use of the Atkins diet for over 1 week
* Significant heart, liver, or kidney disease
```

## Interventions

- **Modified Atkins diet** (BEHAVIORAL)

## Primary Outcomes

- **Seizure control** _(time frame: 6 months)_
- **Ketosis** _(time frame: 6 months)_

## Secondary Outcomes

- **Tolerability** _(time frame: 6 months)_
- **Safety - cholesterol, kidney function, weight** _(time frame: 6 months)_

## Locations (1)

- Johns Hopkins Hospital, Baltimore, Maryland, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.johns hopkins hospital|baltimore|maryland|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00181090.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00181090*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*